AzTrials
AzTrials

Adjunctive Treatment of Major Depressive DisorderPhase 2NCT03018340

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

A Phase 2 study testing Pimavanserin in people with Adjunctive Treatment of Major Depressive Disorder, run by ACADIA Pharmaceuticals Inc. at 36 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an inadequate response to antidepressant therapy Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Pimavanserin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
207 participants
Where
36 sitesUnited States
Study dates
Dec 2016to Oct 2018
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients, aged 18 years and above
  • A clinical diagnosis of major depressive disorder (MDD)
  • Is being treated with one of the following SSRI or SNRI antidepressants as monotherapy:
  • Citalopram
  • Escitalopram
  • Paroxetine
Show all 13Show fewer
  • Fluoxetine
  • Sertraline
  • Duloxetine
  • Venlafaxine
  • Desvenlafaxine
  • Venlafaxine XR
  • Has a history of inadequate response to antidepressant treatments

Who cannot join

  • Patient has a psychotic disorder other than MDD
  • Patient has current evidence of a serious and/or unstable neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program
  • Patient has a history or symptoms of long QT syndrome
  • Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).

Trial locations and contacts

36 sites in 1 country.

36 sites in 1 country

United States36 sites
  • Emory University School of Medicine

    Atlanta, Georgia, 30329

  • Hassman Research Institute

    Berlin, New Jersey, 08009

  • UAB

    Birmingham, Alabama, 35294

  • Meridien Research

    Bradenton, Florida, 34201

  • Neuro-Behavioral Clinical Research

    Canton, Ohio, 44718

  • Carolina Clinical Trials, Inc.

    Charleston, South Carolina, 29407

  • Alam Medical Research, INC

    Chicago, Illinois, 60612

  • Ericksen Research & Development

    Clinton, Utah, 84015

  • FutureSearch Trials of Dallas, L.P.

    Dallas, Texas, 75231

  • UTSW

    Dallas, Texas, 75235

  • iResearch Atlanta

    Decatur, Georgia, 30030

  • Collaborative Neuroscience Network, LLC

    Garden Grove, California, 92845

  • Alexian Brothers Center for Psychiatric Research

    Hoffman Estates, Illinois, 60169

  • Baylor College of Medicine

    Houston, Texas, 77030

  • CNS Health care (Jacksonville)

    Jacksonville, Florida, 32256

  • Altea Research

    Las Vegas, Nevada, 89102

  • BTC of Lincoln

    Lincoln, Rhode Island, 02865

  • Meridien Research

    Maitland, Florida, 32751

  • Synergy San Diego

    National City, California, 91950

  • Manhattan Behavioral Medicine

    New York, New York, 10036

  • Pacific Research Partners, LLC

    Oakland, California, 94607

  • IPS Research

    Oklahoma City, Oklahoma, 73103

  • Rivus Wellness & Research Institute

    Oklahoma City, Oklahoma, 73112

  • CNS Health care (Orlando)

    Orlando, Florida, 32801

  • UPenn

    Philadelphia, Pennsylvania, 19104

  • Summit Research Network (Oregon)

    Portland, Oregon, 97210

  • Pillar Clinical Research

    Richardson, Texas, 75080

  • Finger Lakes Clinical Research

    Rochester, New York, 14618

  • Woodland Research Northwest

    Rogers, Arkansas, 72758

  • Schuster Medical Research Institute

    Sherman Oaks, California, 91403

  • St. Louis Clinical Trials

    St Louis, Missouri, 63141

  • Viking Clinical Research

    Temecula, California, 92591

  • Collaborative Neuroscience Network, LLC

    Torrance, California, 90502

  • Pacific Clinical Research Medical Group

    Upland, California, 91786

  • IPC Research

    Waukesha, Wisconsin, 53188

  • KUMC

    Wichita, Kansas, 67214

Other trials in United States

About this study

Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an inadequate response to antidepressant therapy

Being tested
Pimavanserin, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PimavanserinDrug

    Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.

  • PlaceboOther

    Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.

Study groups in NCT03018340
Study groupRoleWhat they receive
Pimavanserin 34 mg + SSRI/SNRIExperimentalDrug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
Receives: Drug: Pimavanserin
Placebo + SSRI/SNRIPlacebo comparatorPlacebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to Week 5 in the HAMD-17 Total Score

    The Hamilton Rating Scale for Depression (HAMD-17) is a 17-item scale to assess depression. The HAMD-17 consists of 8 items with a score on a 3 point scale and 9 items with a score on a 5 point scale. Each item is rated from least (0) to most frequent or most severe, as applicable, with highest scores of 2 to 4, depending on the item. Items are summed up to calculate the HAMD-17 total score. The total score ranges from 0 to 52. A higher total score indicates more severe depression.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

Secondary outcomes (10)
  1. Change From Baseline to Week 5 in the SDS Total Score

    The Sheehan Disability Scale is a 3-item patient-facing questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point scale from 0 (no impairment) to 10 (most severe). The total SDS score ranges from 0 to 10. It is calculated as the arithmetic mean of the scores for all 3 items. A higher score indicates greater disability.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  2. Treatment Response and Remission Rates at the End of 5-week Treatment Period

    The Hamilton Rating Scale for Depression (HAMD-17) is a 17-item scale to assess depression. Each item is rated from least (0) to most frequent or most severe, as applicable, with highest scores of 2 to 4 depending on the item. Items are summed up to calculate the HAMD-17 total score. A higher total score indicates more severe depression.

    Treatment response was defined as a reduction from Baseline in HAMD-17 total score of >=50%.

    Remission was defined as a HAMD-17 total score <=7.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  3. Change From Baseline to Week 5 in CGI-S Total Score

    The Clinical Global Impression-Severity Scale is a 1-item scale, used to rate the severity of the disorder from 0 (not assessed) to 7 (among the most extremely ill patients). A higher CGI-I score denotes more severe depression.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  4. CGI-I Score at Week 5

    The Clinical Global Impression- Improvement scale is a 1-item scale, used to rate the global improvement of the patient since beginning of the study from 0 (not assessed) to 7 (very much worse). A higher CGI-I score denotes less improvement in depression.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  5. Change From Baseline to Week 5 in SF-12 Score

    The 12-Item Short Form Health Survey is a patient-reported outcome measure that addresses 8 domains of physical functioning, role - physical, bodily pain, general health perceptions, vitality, social functioning, role - emotional, and mental health. Composite scores were obtained representing physical health and mental health composite summaries, Physical Component Summary (PCS) and Mental Component Summary (MCS), respectively. An algorithm was used to generate PCS and MCS for comparison to normative data. In normative data, the mean score was set to 50; thus, scores >50 indicate better physical or mental health than the mean and scores <50 indicate worse health. A higher score is indicative of a better health state.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  6. Change From Baseline to Week 5 in DAI-10 Score

    The Drug Attitude Inventory-10 is a 6-item patient-facing questionnaire to evaluate a patient's perceptions and experiences of treatment. It contains 6 items that a patient who is fully adherent to prescribed medication would answer as "True," and 4 items that a patient who is fully adherent would rate as "False." Scores are allocated to each answer and the total score is calculated as the sum. A correct answer is scored +1 and an incorrect answer is scored -1. The total score ranges from -10 to 10 and is the sum of pluses and minuses. A positive total score indicates a positive subjective response (adherent) and a negative total score indicates a negative subjective response (nonadherent). Higher scores denoted better adherence.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  7. Change From Baseline to Week 5 in KSS Score

    The Karolinska Sleepiness Scale is a patient-facing 1-item scale that measures the patient's drowsiness. Scoring is based on a 9-point verbally anchored scale ranging from "extremely alert" (1) to "very sleepy, great effort to keep awake, fighting sleep" (9). Higher scores denote more drowsiness.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  8. Change From Baseline to Week 5 in MGH-SFI Score

    The Massachusetts General Hospital Sexual Functioning Index is a patient-facing questionnaire that quantifies sexual dysfunction into 5 functional domains ("interest in sex," "sexual arousal," "ability to achieve orgasm," "ability to maintain erection" [males only], and "sexual satisfaction"). Patients rate each item using a 6-point scale ranging from 1 (good function) to 6 (poor function). The MGH-SFI score is calculated as the arithmetic mean of the item scores for the 5 domains. The mean MGH-SFI score ranges from a minimum value of 1 to a maximum value of 6. Higher scores denotes worse sexual dysfunction.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  9. Change From Baseline to Week 5 in BIS-11 Score

    The Barratt Impulsiveness Scale-11 is a questionnaire for assessment of the personality/behavioral construct of impulsiveness. It is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale from Rarely/Never (1) to Almost Always/Always (4). Items are summed up to calculate the total score. The BIS-11 total score ranges from 30 to 120. Higher scores denotes more impulsiveness.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

  10. Change From Baseline to Week 5 in SIS Score

    The Sheehan Irritability Scale is a 7-item patient-reported outcome measure to measure the frequency, severity, and impairment associated with irritability in psychiatric patients. It includes items on: irritability, frustration, edginess/ impatience/ overreaction, moodiness, anger with self, anger with others, and temper. Items are answered on an 11-point rating scale where higher scores indicated greater severity (0=not at all, 10=extremely). Item responses are summed into a total score (range=0-70). Higher scores mean higher irritability.

    Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2017 (estimated)
  2. Study startDec 2016
  3. Primary completionSep 2018
  4. Study completionOct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
207 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03018340
Sponsor's protocol ID
ACP-103-042
Status last verified
Oct 2019
First submitted
10 Jan 2017
Last updated
14 Nov 2019
Data monitoring committee
No
Individual data sharing
No

Publications

  • Jha MK, Fava M, Freeman MP, Thase ME, Papakostas GI, Shelton RC, Trivedi MH, Dirks B, Liu K, Stankovic S. Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. J Clin Psychiatry. 2020 Dec 1;82(1):20m13425. doi: 10.4088/JCP.20m13425.

    PubMed 33264819
  • Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). J Clin Psychiatry. 2019 Sep 24;80(6):19m12928. doi: 10.4088/JCP.19m12928.

    PubMed 31556975

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Pimavanserin in people with Adjunctive Treatment of Major Depressive Disorder, run by ACADIA Pharmaceuticals Inc. at 36 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 36 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 Nov 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to Week 5 in the HAMD-17 Total Score (time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03018340, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in